Complete Genomics Publishes in Science on Low-Cost Sequencing of Three Human Genomes Using Its Proprietary Sequencing Platform

Thu Nov 5, 2009 2:00pm EST

* Reuters is not responsible for the content in this press release.

MOUNTAIN VIEW, Calif.--(Business Wire)--
Complete Genomics, a third-generation human genome sequencing company, today
announced publication of a report in the journal Science describing its
proprietary DNA sequencing platform, including analysis of sequence data from
three complete human genomes. The consumables cost for these three genomes
sequenced on the proof-of-principle genomic DNA nanoarrays ranged from $8,005
for 87x coverage to $1,726 for 45x coverage for the samples described in this
report. 

"We`ve demonstrated that it`s possible to accurately and affordably sequence and
detect variants across entire human genomes," said Cliff Reid, chairman,
president and CEO of Complete Genomics. "This high-quality, cost-effective
approach to genome sequencing will allow researchers to study complete genomes
from hundreds of patients with a disease to advance the understanding of the
genetic causes of that disease, with an end to preventing and treating common
human ailments." 

The manuscript, titled, "Human Genome Sequencing Using Unchained Base Reads on
Self-Assembling DNA Nanoarrays," describes the methodology used to sequence cell
lines derived from two individuals previously characterized by the International
HapMap project. These included a Caucasian male of European descent (NA07022)
and a Yoruban female (NA19240). In addition, researchers sequenced lymphoblast
DNA from a Caucasian male sample (NA20431) obtained from the Personal Genome
Project (www.PersonalGenomes.org). 

Complete Genomics` proprietary platform enables efficient imaging, while
requiring low reagent consumption, through its combinatorial probe anchor
ligation (cPAL) chemistry and its use of patterned genomic DNA nanoarrays. With
this approach, Complete Genomics` scientists generated high-quality diploid base
calls in as much as 95 percent of the genomes sequenced, identifying 3.2 million
to 4.5 million sequence variants per genome processed. 

Detailed validation of one genome dataset demonstrates a sequence accuracy of
just one false variant per 100 kilobases, a remarkably low error rate,
particularly for such an affordable technology. 

Patterned genomic DNA nanoarrays and 70-base, unchained sequence reads are
unique technical achievements. The company`s new patterned genomic DNA
nanoarrays, which achieve a record high density of 2.85 billion spots per slide
at 0.7 micron pitch, will enable Complete Genomics to sequence 10,000 human
genomes in 2010. 

About Complete Genomics

Founded in 2006, Complete Genomics is a California company that has developed a
novel approach to sequencing human DNA that is revolutionizing the human genome
sequencing industry. Complete Genomics combines its proprietary third-generation
DNA sequencing technology with its high-performance computing capabilities to
deliver low-cost, high-quality genomic data on an unprecedented scale. The
company is currently building the world`s largest human genome sequencing
center. This development will allow academic and biopharmaceutical researchers,
for the first time, to conduct large-scale complete human genome studies that
will help identify the genetic underpinnings of complex diseases and drug
responses. For additional information about the company, please visit
http://www.completegenomics.com.

Complete Genomics Inc.
Jennifer Turcotte, Vice President of Marketing, 650-943-2846
jturcotte@completegenomics.com
or
Waggener Edstrom Worldwide Healthcare
Lisa Osborne, Account Director, 202-261-7806
lisao@waggeneredstrom.com

Copyright Business Wire 2009

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.